Inquiry Basket
Loading ......
Benralizumab is a humanized afucosylated immunoglobulin gamma one kappa (IgG1κ) monoclonal antibody that targets the interleukin-5 receptor alpha subunit (IL-5Rα), which is expressed on the surface of eosinophils and basophils. By binding to IL-5Rα, Benralizumab blocks the interaction between interleukin-5 and its receptor, thereby inhibiting the survival, activation, and proliferation of eosinophils. However, the unique feature of Benralizumab that distinguishes it from other anti-eosinophil therapies is its ability to induce potent antibody-dependent cell-mediated cytotoxicity through its afucosylated Fc region, resulting in near-complete depletion of eosinophils from blood and tissues.The successful clinical use of Benralizumab depends on accurate bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic monitoring. Reliable quantification of Benralizumab concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response, optimizing dosing regimens, and ensuring patient safety. Additionally, detection of anti-Benralizumab antibodies is critical for evaluating the immunogenicity profile of this therapeutic antibody, as treatment-emergent anti-drug antibodies can alter pharmacokinetics, reduce efficacy, and potentially trigger adverse events such as infusion-related reactions.
Figure 1. Anti-Benralizumab ELISA Kit for Immunogenicity Monitoring.
Interleukin-5 is a cytokine produced primarily by T helper type two cells, mast cells, and innate lymphoid cells. It plays a central role in the differentiation, maturation, recruitment, activation, and survival of eosinophils, a subset of granulocytes involved in allergic inflammation and host defense against parasitic infections. In eosinophilic asthma, overproduction of interleukin-5 drives the accumulation of eosinophils in the airways, where they release cytotoxic granule proteins, lipid mediators, and cytokines that contribute to airway inflammation, mucus hypersecretion, and tissue remodeling. The interleukin-5 receptor is a heterodimeric complex composed of a unique alpha subunit (IL-5Rα) that confers ligand specificity and a common beta subunit shared with the receptors for interleukin-3 and granulocyte-macrophage colony-stimulating factor. IL-5Rα is expressed almost exclusively on eosinophils and basophils, providing a highly selective target for therapeutic intervention. The restricted expression pattern of IL-5Rα minimizes the potential for off-target effects, making it an attractive target for monoclonal antibody therapy.
Benralizumab exerts its effects through two complementary mechanisms. First, Benralizumab binds to IL-5Rα with high affinity, blocking the interaction between interleukin-5 and its receptor. This competitive antagonism prevents interleukin-5 mediated signaling, inhibiting eosinophil survival, activation, and proliferation. Second, Benralizumab is afucosylated, meaning it lacks fucose sugar residues in its Fc region. This afucosylation enhances the binding affinity of Benralizumab for Fc gamma receptor IIIa on natural killer cells and other immune effector cells, potently augmenting antibody-dependent cell-mediated cytotoxicity. The combination of IL-5Rα blockade and enhanced antibody-dependent cell-mediated cytotoxicity results in rapid and near-complete depletion of eosinophils from blood and tissues. Unlike other anti-eosinophil therapies that only inhibit eosinophil activation or survival, Benralizumab actively eliminates eosinophils through immune effector cell engagement. This profound depletion is sustained for many months following a single dose, supporting the extended dosing interval of every eight weeks after the initial loading doses.
Benralizumab has demonstrated robust efficacy in patients with severe eosinophilic asthma. In pivotal phase three trials, Benralizumab significantly reduced the annual exacerbation rate compared to placebo, improved pre-bronchodilator forced expiratory volume in one second, and reduced the use of maintenance oral corticosteroids. The magnitude of benefit was greatest in patients with the highest baseline blood eosinophil counts, supporting the use of eosinophil levels as a predictive biomarker. The safety profile of Benralizumab is generally favorable. The most common adverse events include headache, nasopharyngitis, and injection site reactions. The risk of serious infections, including opportunistic infections, does not appear to be increased compared to placebo, consistent with the notion that eosinophils are not essential for host defense against most pathogens. However, patients with parasitic infections are generally excluded from treatment due to the theoretical risk of impaired parasite clearance.
| Key Molecular Targets | Details |
| Importance of Drug Quantification | Pharmacokinetic characterization describes the time course of Benralizumab concentrations in the body following administration. Reliable quantification of drug concentrations in serum or plasma is essential for understanding the relationship between dose and exposure, evaluating the impact of patient characteristics on drug levels, and supporting dosing regimen optimization. The concentration of Benralizumab in circulation is determined by the balance between drug input from subcutaneous administration and drug elimination. Benralizumab exhibits target-mediated clearance due to binding to IL-5Rα on eosinophils and basophils. As eosinophils are depleted following treatment, target-mediated clearance decreases, resulting in nonlinear pharmacokinetics with lower clearance at higher concentrations. |
| Therapeutic Monitoring Considerations | Therapeutic drug monitoring involves measuring drug concentrations in individual patients to guide dosing decisions. For Benralizumab, the relationship between drug exposure and clinical response has been characterized in population pharmacokinetic-pharmacodynamic models. Factors that influence Benralizumab exposure include body weight, baseline eosinophil count, and the presence of anti-drug antibodies. |
The Anti-Benralizumab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Benralizumab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
The Free Benralizumab ELISA Kit is designed for the quantitative determination of free Benralizumab concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic monitoring applications.
Benralizumab represents a unique and effective therapy for severe eosinophilic asthma, utilizing both IL-5Rα blockade and enhanced antibody-dependent cell-mediated cytotoxicity to achieve profound eosinophil depletion. Reliable bioanalytical methods are essential for supporting the clinical development and optimal use of this therapeutic antibody. The Anti-Benralizumab ELISA Kit provides a validated, sensitive, and specific solution for detecting anti-Benralizumab antibodies, supporting immunogenicity assessment that meets regulatory expectations. The Free Benralizumab ELISA Kit enables accurate quantification of unbound drug concentrations, facilitating pharmacokinetic characterization and therapeutic drug monitoring. Together, these kits provide a comprehensive bioanalytical toolkit for researchers and clinicians working with Benralizumab across all stages of development and clinical use.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25236 | Anti-Benralizumab ELISA Kit | Human | sELISA | Inquiry |
| DEIA-JY25253 | Free Benralizumab ELISA Kit | Human | sELISA | Inquiry |
Loading ......
